Fund overview & performance

Asset class

Based on three-year return


Annualized returns

Between % and %

 


Fund management

Series

Clear all filters

Canada Life International Concentrated Equity Fund

July 31, 2025

The Fund seeks to achieve long-term capital appreciation by investing primarily in equity securities of companies in any country outside of Canada and the United States.

Is this fund right for you?

  • You want your money to grow over a longer term.
  • You want to invest in companies outside of Canada and the U.S.
  • You're comfortable with a medium level of risk.

Risk Rating

Risk Rating: Medium

How is the fund invested? (as of May 31, 2025)

Asset allocation (%)

Name Percent
International Equity 94.9
US Equity 4.0
Cash and Equivalents 1.1

Geographic allocation (%)

Name Percent
France 15.8
United Kingdom 15.4
Japan 14.6
Germany 12.7
Sweden 8.0
India 6.0
Switzerland 5.8
Taiwan 4.7
United States 4.0
Other 13.0

Sector allocation (%)

Name Percent
Industrial Goods 19.0
Consumer Goods 16.9
Financial Services 16.3
Technology 12.0
Healthcare 10.4
Real Estate 9.7
Basic Materials 4.7
Industrial Services 3.9
Consumer Services 3.4
Other 3.7

Growth of $10,000 (since inception)

Data not available based on date of inception

Fund details (as of May 31, 2025)

Top holdings %
HDFC Bank Ltd - ADR 6.0
L'Air Liquide SA 4.7
Sap SE 4.7
Taiwan Semiconductor Manufactrg Co Ltd - ADR 4.7
Deutsche Boerse AG Cl N 4.3
Sony Group Corp 4.1
Ferguson Enterprises Inc 4.0
Relx PLC 3.9
Siemens AG Cl N 3.8
Nestle SA Cl N 3.8
Total allocation in top holdings 44.0
Portfolio characteristics
Standard deviation 12.6%
Dividend yield 1.8%
Average market cap (million) $234,770.9

Understanding returns

Annual compound returns (%)

1 MO 3 MO YTD 1 YR
{{snapShot.Return1Mth|customNumber:1}}{{snapShot.Return3Mth|customNumber:1}}{{snapShot.ReturnYTD|customNumber:1}}{{snapShot.Return1Yr|customNumber:1}}
3 YR 5 YR 10 YR INCEPTION
{{snapShot.Return3Yr|customNumber:1}}{{snapShot.Return5Yr|customNumber:1}}{{snapShot.Return10Yr|customNumber:1}}{{snapShot.ReturnInception|customNumber:1}}

Calendar year returns (%)

2024 2023 2022 2021
{{snapShot.Return1YrCalendar|customNumber:1}}{{snapShot.Return2YrCalendar|customNumber:1}}{{snapShot.Return3YrCalendar|customNumber:1}}{{snapShot.Return4YrCalendar|customNumber:1}}
2020 2019 2018 2017
{{snapShot.Return5YrCalendar|customNumber:1}}{{snapShot.Return6YrCalendar|customNumber:1}}{{snapShot.Return7YrCalendar|customNumber:1}}{{snapShot.Return8YrCalendar|customNumber:1}}

Range of returns over five years (November 1, 2018 - July 31, 2025)

Best return Best period end date Worst return
Worst period end date
12.5% Aug. 2024 9.1% July 2025
Average return % of periods with positive returns Number of positive periods Number of negative periods
11.1% 100.0% 22 0

Q2 2025 Fund Commentary

Market commentary

International equities rose to new highs during the second quarter of 2025, but key risks remained. Global trade tensions, rising U.S. debt and weak U.S. gross domestic product growth continued to affect market sentiment. This was compounded by the threat of higher oil prices amid tensions in the Middle East.

Macroeconomic data pointed to rising recession risk, and June saw widespread downward revisions to growth forecasts. Trade policy uncertainty clouded the economic outlook, with tariff disruptions affecting inflation expectations and business investment. The European Central Bank made its eighth interest-rate cut, while the U.S. Federal Reserve Board kept interest rates steady.

Performance

The Fund’s relative exposure to Ferguson Enterprises Inc. and Taiwan Semiconductor Manufacturing Co. Ltd. (TSMC) had the most positive impact on performance. Ferguson benefited from revenue growth and market share gains, raising its full-year 2025 outlook. TSMC’s May revenue was better than expected, up 40% year over year.

Relative exposure to AstraZeneca PLC was negative for performance. Its shares fell along with its peers when the U.S. administration announced plans to cut U.S. prescription drug costs.

At the sector level, stock selection in financials and information technology had the most positive impact on the Fund’s performance. Overweight exposure to industrials and information technology also had a positive impact. Security selection in industrials was negative for performance.

At a regional level, overweight exposure to India had a positive impact on performance. Overweight exposure to Sweden and underweight exposure to Japan had a negative impact.

Portfolio activity

The sub-advisor added Galderma Group AG, the world’s largest independent dermatology company, to the Fund. It operates in the fastest-growing segments of the dermatology market. The company has a strong track record of above-market growth, underpinned by long-term trends, premium brand positioning and high barriers to entry.

Daikin Industries Ltd. was sold in favour of buying Heidelberg Materials AG. Daikin’s stock performed well, but China’s real estate slump exposed the company’s profit reliance on the region. The sub-advisor believes Heidelberg Materials, a global supplier of heavy building materials, should benefit from European fiscal stimulus, tightening carbon regulations and margin improvement.

Outlook

Le fonds est constitué d’une combinaison équilibrée de sociétés affichant différents degrés de croissance. Le sous-conseiller privilégie les entreprises de croissance qui génèrent de bons niveaux de flux de trésorerie et présentent un bilan solide. Le sous-conseiller estime que ces caractéristiques sont importantes dans le contexte actuel de marché incertain, ainsi qu’à long terme.

C WorldWide Asset Management

Contact information

Toll free: 1-844-730-1633

{{ snapShot.FundName.replace("<em>", "").replace("</em>", "") }}
No matching records found.

Summary

For the period {{NAVPSPerformanceSummary.StartDate}} through {{NAVPSPerformanceSummary.EndDate}} with $10,000 CAD investment

Total returns performance

{{NAVPSPerformanceSummary.Growth | customPercentage}}

Last price

{{NAVPSPerformanceSummary.NAVPS | customCurrency}} CAD

as of market close {{NAVPSPerformanceSummary.NAVPSDate}}

Value of $10,000 investment

{{NAVPSPerformanceSummary.GrowthOfTenThousand | customCurrency}} CAD

Export to: